Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Hepatology

• Publication date

  2014-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jhep.2013.10.021PMID 24398036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction of HBV replication prolongs the early immunological response to IFNα therapy.

  2014cited by this paper
• Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.

  2013cited by this paper
• Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?

  2013cited by this paper
• Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity

  2013cited by this paper
• Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.

  2013cited by this paper
• Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.

  2012cited by this paper
• Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene

  2012cited by this paper
• Pegylated Interferon Results in Higher Serological, but Not Virological, Response Rates When Compared to Continuous Entecavir

  2012cited by this paper
• Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.

  2012cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.

  2012cited by this paper
• New perspectives in the therapy of chronic hepatitis B

  2012cited by this paper
• Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2B: Relation to Response and HBV Genotype

  2012cited by this paper
• New insight in the pathobiology of hepatitis B virus infection

  2012cited by this paper
• Chimeric mouse model of hepatitis B virus infection.

  2012cited by this paper
• The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway.

  2011cited by this paper
• Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.

  2011cited by this paper
• Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

  2011cited by this paper
• Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice.

  2011cited by this paper
• Interferons Accelerate Decay of Replication-Competent Nucleocapsids of Hepatitis B Virus

  2010cited by this paper
• Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients

  2010cited by this paper
• Impaired TLR3/IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage.

  2009cited by this paper
• Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

  2009cited by this paper
• Alpha Interferon Induces Long-Lasting Refractoriness of JAK-STAT Signaling in the Mouse Liver through Induction of USP18/UBP43

  2009cited by this paper
• Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients

  2009cited by this paper
• Control of cccDNA function in hepatitis B virus infection.

  2009cited by this paper
• Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus

  2009cited by this paper
• Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B

  2009cited by this paper
• Hepatitis B virus suppresses toll‐like receptor–mediated innate immune responses in murine parenchymal and nonparenchymal liver cells

  2009cited by this paper
• Sequential Combination Therapy Leads to Biochemical and Histological Improvement Despite Low Ongoing Intrahepatic Hepatitis B virus Replication

  2008cited by this paper
• Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection

  2008cited by this paper
• Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection

  2007cited by this paper
• Evaluation of a cyclophilin inhibitor in hepatitis C virus–infected chimeric mice in vivo

  2007cited by this paper
• Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.

  2007cited by this paper
• Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones.

  2006cited by this paper
• Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

  2006cited by this paper
• One-Year Entecavir or Lamivudine Therapy Results in Reduction of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA Levels

  2005cited by this paper
• Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids.

  2005cited by this paper
• Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.

  2005cited by this paper
• Management of chronic hepatitis B virus infection

  2004cited by this paper

• Interferon-α for Immune Modulation in Chronic Hepatitis B Toward Functional Cure

  2025cites this paper
• Altered LY6E and TRIM6 expression in PBMCs correlated with HBsAg clearance and response to Peg-IFN-α treatment in HBeAg-negative chronic hepatitis B patients

  2025cites this paper
• HBV cccDNA: The Molecular Reservoir of Hepatitis B Persistence and Challenges to Achieve Viral Eradication

  2025cites this paper
• Classification of the LC4 Primarily-like Cell Line—Recapitulating a CDK4 Overexpressing Immune Evasive HIV-HCV-Induced HCC

  2025cites this paper
• Targeting HBV with RNA interference: Paths to cure.

  2025cites this paper
• Augmented epigenetic repression of hepatitis B virus covalently closed circular DNA by interferon-α and small-interfering RNA synergy

  2024cites this paper
• A CRISPR-based system to investigate HBV cccDNA biology

  2023cites this paper
• Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy.

  2023cites this paper
• Development of animal models for emerging infectious diseases by breaking the barrier of species susceptibility to human pathogens

  2023cites this paper
• Intrahepatic transcriptomics reveals gene signatures in chronic hepatitis B patients responded to interferon therapy

  2022cites this paper
• IFNα subtype-specific susceptibility of HBV in the course of chronic infection

  2022cites this paper
• Innate Immunity, Inflammation, and Intervention in HBV Infection

  2022cites this paper
• A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

  2022cites this paper
• Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells

  2022cites this paper
• Methylation profile of hepatitis B virus is not influenced by interferon α in human liver cancer cells

  2021cites this paper
• Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition

  2021cites this paper
• Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo

  2021cites this paper
• Interferon and Hepatitis B: Current and Future Perspectives

  2021cites this paper
• Functional Comparison of Interferon‐α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon‐α and Interferon‐γ Signaling

  2020cites this paper
• Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon‐α in Woodchucks Chronically Infected With Woodchuck Hepatitis Virus

  2020cites this paper
• cccDNA Maintenance in Chronic Hepatitis B – Targeting the Matrix of Viral Replication

  2020cites this paper
• Epigenetic modulation in chronic hepatitis B virus infection

  2020influential citation
• Hepatitis B Virus cccDNA: Formation, Regulation and Therapeutic Potential.

  2020cites this paper
• T cell receptor grafting allows virological control of Hepatitis B virus infection.

  2019cites this paper
• Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection.

  2019cites this paper
• Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B

  2019cites this paper
• Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

  2019cites this paper
• Development of antiviral drugs against hepatitis B virus

  2019cites this paper
• HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy "Loss of HBsAg" maybe not a good end-point of anti-viral therapy.

  2019cites this paper
• Humanized mouse models for human viral hepatitis and related liver diseases

  2019cites this paper
• No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B

  2018cites this paper
• Interaction between macrophages, hepatocytes and hepatitis B virus : from reprogramming of macrophages phenotypes towards establishment and maintenance of the infection

  2018cites this paper
• Hepatitis B virus sensitivity to interferon‐α in hepatocytes is more associated with cellular interferon response than with viral genotype

  2018cites this paper
• ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection.

  2018cites this paper
• Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.

  2018cites this paper
• Natural history of serum HBV‐RNA in chronic HBV infection

  2018cites this paper
• Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.

  2017cites this paper
• Animal models of HBV infection.

  2017cites this paper
• Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice

  2017cites this paper
• A novel orally available small molecule that inhibits hepatitis B virus expression.

  2017cites this paper
• Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice

  2017cites this paper
• The Role of cccDNA in HBV Maintenance

  2017cites this paper
• T-cell therapy for chronic viral hepatitis.

  2017cites this paper
• Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo

  2017cites this paper
• Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection

  2017cites this paper
• Haem oxygenase‐1 polymorphisms can affect HCV replication and treatment responses with different efficacy in humanized mice

  2017cites this paper
• Interferon-alpha treatment rapidly clears Hepatitis E virus infection in humanized mice

  2017cites this paper
• A Role for the Host DNA Damage Response in Hepatitis B Virus cccDNA Formation—and Beyond?

  2017cites this paper
• Immunofluorescent Staining for the Detection of the Hepatitis B Core Antigen in Frozen Liver Sections of Human Liver Chimeric Mice.

  2017cites this paper
• Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.

  2017cites this paper
• Mechanisms behind TB, HBV, and HIV chronic infections.

  2017cites this paper
• T cell--associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model

  2017cites this paper
• Altered expression of interferon‐stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection

  2017cites this paper
• Humanized Mouse Models of Clinical Disease.

  2017cites this paper
• IFNA2 p.Ala120Thr impairs the inhibitory activity of Interferon‐&agr;2 against the hepatitis B virus through altering its binding to the receptor

  2017cites this paper
• Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection.

  2017influential citation
• Different antiviral effects of IFNα and IFNβ in an HBV mouse model.

  2017cites this paper
• Novel monitoring of hepatitis B reactivation based on ultra‐high sensitive hepatitis B surface antigen assay

  2017cites this paper
• Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

  2016cites this paper
• Experimental Models: Cell Culture and Animal Models

  2016cites this paper
• X: On the molecular biology of the hepatitis B virus X protein

  2016cites this paper
• A Slow Maturation Process Renders Hepatitis B Virus Infectious.

  2016cites this paper
• Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation.

  2016cites this paper
• Latest developments in the treatment of hepatitis B.

  2016cites this paper
• Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure.

  2016cites this paper
• Experimental in vitro and in vivo models for the study of human hepatitis B virus infection.

  2016cites this paper
• Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.

  2016cites this paper
• Dynamics of in vivo hepatitis D virus infection.

  2016cites this paper
• Validation of Cross-Genotype Neutralization by Hepatitis B Virus-Specific Monoclonal Antibodies by In Vitro and In Vivo Infection

  2015cites this paper
• Therapeutic Alpha-Interferons Protein: Structure, Production, and Biosimilar

  2015cites this paper
• Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B

  2015cites this paper
• Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation

  2015cites this paper
• Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections

  2015cites this paper
• Neue Entwicklungen in der Therapie der Hepatitis B

  2015cites this paper
• Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?

  2015cites this paper
• Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure.

  2015cites this paper
• New insights into hepatitis B virus biology and implications for novel antiviral strategies

  2015cites this paper
• Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies.

  2015cites this paper
• Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management.

  2014cites this paper
• Host Factor-Targeted Hepatitis B Virus Therapies

  2014cites this paper
• Mouse models of hepatitis B and delta virus infection.

  2014influential citation
• Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance

  2014cites this paper